IL-6 and IL-6R Blockade for CRS Management

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

At Creative Biolabs, we empower our scientists and engineers to accelerate the progress of our clients' programs and enable the development of novel drugs to manage the cytokine release syndrome (CRS) caused by T cell engaging immunotherapies. We bring creative minds together for a common goal: facilitating the drug discovery and development for CRS management to improve the safety of T cell engaging immunotherapies.

Background

CAR-T cell therapy and T cell engaging antibodies have demonstrated significant anti-tumor efficacy in recent clinical trials. The hallmark of these therapies is T cell activation, leading to not only increased adaptive anti-tumor efficacy but also notable severe toxicities in some cases. CRS, caused by T cell activation, is correlated with both efficacy and toxicity. The most significantly elevated cytokines include interferon-γ, interleukin (IL)-10 and IL-6. IL-6 is an inflammatory cytokine involved in a variety of immune responses. IL-6 is not sure to play a must role for the efficacy of immunotherapies, making it a potentially desirable target for toxicity management. Taken together, one strategy to provide superior toxicity control without compromising efficacy is targeting IL-6 or IL-6R.

Fig.1 Several modes of IL-6 receptor signaling. (Kang, 2019)

IL-6 and IL-6R Blockade for CRS Management

By combining experienced immunotherapy development solutions, streamlined process improvement, and cutting-edge technologies, Creative Biolabs provides integrated, science-driven, drug development services to enable our clients to achieve their drug discovery goals targeting IL-6/IL-6R, a key signaling cascade. We are dedicated to offering rigorous scientific expertise to ensure the most accurate and high-quality results. Targeting proteins are not limited to IL-6/IL-6R, some other signaling proteins can also be investigated to explore more possibilities, such as JAK, STAT3. For drug modalities, both monoclonal antibodies and small-molecule inhibitors are within our service scope. The following strategies are for your reference only. Please reach out to our scientists for consultancy and specific design to fit your programs.

Anti-IL-6 mAb
Anti-IL-6R mAb
JAK inhibitor
STAT3 inhibitor

Fig.2 Extracellular and intracellular inhibitors for IL-6 signaling. (Kang, 2019)

Highlight Features

Ideal consulting partner to assist with your drug discovery for CRS management
Advanced speed and precision while ensuring high-quality outcomes
A value-added CRO with a focus on drug development for CRS management

At Creative Biolabs, our scientists not only work with their minds but also put their passion into the programs. We are glad to take challenges to accomplish various drug discovery and development programs. With senior scientists and more than 10 years'CRO services, we are committed to facilitating the success of your programs leveraging our full group-wide potential. Please contact us for more details.

References

Khadka, Roman H., et al. "Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies." Immunotherapy 11.10 (2019): 851-857.
Kang, Sujin, et al. "Targeting interleukin-6 signaling in clinic." Immunity 50.4 (2019): 1007-1023.
Maude, Shannon L., et al. "Managing cytokine release syndrome associated with novel T cell-engaging therapies." Cancer journal (Sudbury, Mass.) 20.2 (2014): 119.
Kang, Sujin, Toshio Tanaka, and Tadamitsu Kishimoto. "Therapeutic uses of anti-interleukin-6 receptor antibody." International immunology 27.1 (2014): 21-29.